Using a blood test to guide treatment for advanced pancreatic cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests whether a blood test that detects tumor DNA can help doctors decide early if the standard chemotherapy is working, and if switching treatment might be better. It is for people newly diagnosed with metastatic pancreatic cancer who are starting their first chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with pancreatic cancer that has spread to other parts of the body.
- You have not received any treatment for metastatic pancreatic cancer yet.
- You must have a blood test that shows tumor DNA can be detected.
- You have at least one tumor that can be seen on a CT or PET scan.
- You are 18 years or older and not pregnant or breastfeeding.
- You have good enough organ function, like enough blood cells and kidney/liver health.
- Your doctor says you are healthy enough for daily activities (ECOG score 0 or 1).
- You are able to receive the chemotherapy regimen called modified FOLFIRINOX.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests how well targeted medicines (and possibly an immunotherapy drug) work for people with pancreatic cancer that can’t be fully removed with surgery or has spread. It also looks at whether the treatment is safe and can shrink or control tumors by blocking specific cancer pathways.
This Phase 3 study tests whether people with pancreatic cancer should get standard chemo or a chemo plan guided by a tumor gene/RNA test after surgery. It aims to see if the right chemo choice for your tumor biology can improve outcomes after your tumor is removed.
This Phase 2 study compares two chemotherapy combinations to treat metastatic pancreatic cancer that has progressed after gemcitabine (with or without Abraxane). It aims to see which combination works better and is tolerable for people with measurable disease.
This trial is for people who had surgery for pancreatic cancer and are now deciding on maintenance therapy. A special blood test (ctDNA) may help doctors choose the best follow-up treatment to prevent the cancer from coming back.
This trial tests a method that analyzes your tumor's genes and grows a mini-tumor in a dish to find which drugs might work best for your metastatic pancreatic cancer. It aims to improve treatment choices by using these personalized tests.
This trial studies whether a blood test (ctDNA, a DNA signal from tumors) can help track how pancreatic cancer responds during planned conversion therapy. It may help doctors spot treatment response earlier and guide next steps.
Hear when a new Metastatic Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.